Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03000439
Recruitment Status : Recruiting
First Posted : December 22, 2016
Last Update Posted : May 18, 2023
Sponsor:
Information provided by (Responsible Party):
Pfizer

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA flare. Once 31 flares are reported the study will be completed.

Condition or disease Intervention/treatment Phase
Arthritis Juvenile Idiopathic Drug: In open-label phase: treatment with tofacitinib Drug: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS
Actual Study Start Date : May 10, 2018
Estimated Primary Completion Date : March 26, 2024
Estimated Study Completion Date : March 26, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Arthritis

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Tofacitinib 5 mg BID
oral, twice daily, tablet or solution.
 Drug: In open-label phase: treatment with tofacitinib
Treatment with investigational drug
Other Names:
  • CP-690,550
  • Xeljanz

Drug: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
Treatment with investigational drug or placebo
Other Names:
  • CP-690,550
  • Xeljanz
Placebo Comparator: Placebo Drug: In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
Treatment with investigational drug or placebo
Other Names:
  • CP-690,550
  • Xeljanz


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Time to flare [ Time Frame: Up to 82 weeks after randomization ]
    Time to sJIA disease flare in the double-blind phase


Secondary Outcome Measures :
  1. Occurrence of disease flare in double-blind phase [ Time Frame: Up to 82 weeks after randomization ]
    disease flare frequency by visit in the double-blind phase.

  2. Achievement of corticosteroid tapering at the end of the open-label phase [ Time Frame: 12 to 40 weeks ]
    Rate of successful corticosteroid tapering.

  3. Achievement of a corticosteroid dose of 0.2 mg/kg/day or 10 mg/day (whichever is lower) at the end of the open label treatment period [ Time Frame: 12 to 40 weeks ]
  4. Adapted sJIA ACR 30/50/70/90/100 response at every visit from Day 7 onward in the open label and double blind phase. [ Time Frame: Up to 82 weeks after randomization ]
  5. Fever (Temp >38 Degrees Celsius) attributed to sJIA at Day 3, Day 7 and Day 14 of the open label phase. [ Time Frame: Day 3, Day 7, Day 14 ]
  6. CRP ≤ 10 mg/L at every visit of the open label phase. [ Time Frame: 12 to 40 weeks ]
  7. "Absence of fever", defined as absence of fever due to sJIA in the week preceding the assessment at every visit from Day 7 onward in the open label and double blind phase. [ Time Frame: Up to 82 weeks after randomization. ]
  8. Time to first Adapted JIA ACR 30 response in Part 1 of the open label phase. [ Time Frame: 12 to 40 weeks ]
  9. Change from baseline in Juvenile Arthritis Disease Activity Score (JADAS 27) at every visit from Day 7 onward in the open label and double blind phase. [ Time Frame: Up to 82 weeks after randomization. ]
  10. Change from baseline in each JIA ACR core variable at every visit from Day 7 onward in the open label and double blind phase. [ Time Frame: Up to 82 weeks after randomization. ]
  11. Change from baseline in Child Health Questionnaire (CHQ) responses at the end of Part 1 and Part 2 of the open label phase, at randomization and every 3 months thereafter. [ Time Frame: Up to 82 weeks after randomization. ]
  12. Change from baseline in Child Health Assessment Questionnaire (CHAQ) at every visit from Day 7 onward in the open label and double blind phase. [ Time Frame: Up to 82 weeks after randomization. ]
  13. Occurrence of inactive disease status and minimal disease activity clinical remission at every visit from Day 7 onward (JADAS 27) in the open label and double blind phase. [ Time Frame: Up to 82 weeks after randomization. ]
  14. Occurrence of inactive disease status and clinical remission at every visit from Day 7 onward (JIA ACR) in the open label and double blind phase. [ Time Frame: Up to 82 weeks after randomization. ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • active sJIA disease according to ILAR criteria before screening and at baseline (Day 1);
  • Treatment with stable doses of methotrexate (MTX) ≤25 mg/week or ≤20 mg/m2/week, whichever is lower, is permitted;
  • Treatment with a stable dose of oral prednisone ≤1 mg/kg/day up to a maximum of 30 mg/day, or equivalent, for at least 1 week before the first study drug dose is permitted.

Exclusion Criteria:

  • Previous juvenile idiopathic arthritis (JIA) treatment with tofacitinib.
  • Current symptoms or findings of myocarditis, endocarditis or more than minimal pericardial effusion associated with systemic juvenile idiopathic arthritis (sJIA). Current symptoms or findings of more than minimal pleuritis with sJIA.
  • Current infection or serious infection within 3 months of study enrollment.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03000439


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Locations
Show Show 99 study locations
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT03000439    
Other Study ID Numbers: A3921165
2017-002018-29 ( EudraCT Number )
First Posted: December 22, 2016    Key Record Dates
Last Update Posted: May 18, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
systemic Juvenile Idiopathic Arthritis
Xeljanz
Tofacitinib
sJIA
CP-690 550
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Joint Diseases
Musculoskeletal Diseases
Tofacitinib
 Janus Kinase Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action